Evidence map›Paper›PMID 35602477›Full record

ReviewFrontiers in medicine2022

The Emergence of SARS-CoV-2 Variants With a Lower Antibody Response: A Genomic and Clinical Perspective.

Suvro Biswas, Shafi Mahmud, Mohasana Akter Mita, Shamima Afrose, Md Robiul Hasan, Gobindo Kumar Paul, Mst Sharmin Sultana Shimu, Md Salah Uddin, Shahriar Zaman, Moon Nyeo Park and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Suvro BiswasMiocrobiology Laboratory, Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Shafi MahmudMiocrobiology Laboratory, Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Mohasana Akter MitaDepartment of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Shamima AfroseDepartment of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Md Robiul HasanDepartment of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Gobindo Kumar PaulMiocrobiology Laboratory, Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Mst Sharmin Sultana ShimuDepartment of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Md Salah UddinMiocrobiology Laboratory, Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Shahriar ZamanMiocrobiology Laboratory, Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Moon Nyeo ParkDepartment of Pathology, College of Korean Medicine, Kyung Hee University, Seoul, South Korea.
Abolghasem SiyadatpanahFerdows School of Paramedical and Health, Birjand University of Medical Sciences, Birjand, Iran.
Ahmad J ObaidullahDrug Exploration and Development Chair (DEDC), Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Md Abu SalehMiocrobiology Laboratory, Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Jesus Simal-GandaraNutrition and Bromatology Group, Department of Analytical Chemistry and Food Science, Faculty of Science, University of Vigo, Ourense, Spain.
Bonglee KimDepartment of Pathology, College of Korean Medicine, Kyung Hee University, Seoul, South Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of several novel SARS-CoV-2 variants regarded as variants of concern (VOCs) has exacerbated pathogenic and immunologic prominences, as well as reduced diagnostic sensitivity due to phenotype modification-capable mutations. Furthermore, latent and more virulent strains that have arisen as a result of unique mutations with increased evolutionary potential represent a threat to vaccine effectiveness in terms of incoming and existing variants. As a result, resisting natural immunity, which leads to higher reinfection rates, and avoiding vaccination-induced immunization, which leads to a lack of vaccine effectiveness, has become a crucial problem for public health around the world. This study attempts to review the genomic variation and pandemic impact of emerging variations of concern based on clinical characteristics management and immunization effectiveness. The goal of this study is to gain a better understanding of the link between genome level polymorphism, clinical symptom manifestation, and current vaccination in the instance of VOCs.

Indexed as

antibodyclinical perspectivegenomic variationSARS-CoV-2variant of concern

Identifiers

PMID35602477
PMCPMC9121733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.